drugset / Trial / NCT03128879
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
NaSingle-groupOpen-labelTreatment
Summary
This is a single center, open-label, phase II study of venetoclax (ABT-199) added to ibrutinib or acalabrutinib in patients with high-risk CLL who have received at least 12 months of ibrutinib or acalabrutinib monotherapy. The study will estimate the therapeutic efficacy of venetoclax consolidation in patients who have detectable CLL after receiving ibrutinib or acalabrutinib for at least 12 months and who have high risk CLL.
Timeline
- Start
- 2017-06-16
- Primary completion
- 2027-05-31
- Completion
- 2027-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Venetoclax | Small molecule | — | Oral |
| Background | Acalabrutinib | Small molecule | — | Oral |
| Background | Ibrutinib | Small molecule | — | Oral |